ROLLING MEADOWS, IL, March 14, 2018 -- OneLife Technologies Corp. (“OneLife” or the “Company”) (OTC PINK: OLMM), a mobile medical data and technologies company, today announced that on March 8, 2018, it was made aware by OTC Markets of promotional activities surrounding the Company's common stock.
The Company immediately initiated an internal investigation into this matter and made inquiries of its executive officers, directors, controlling shareholders (i.e., shareholders owning 10% or more of the Company's securities, of which there is one (1)) and third-party service providers. The Company has made direct inquiries of its executive officers, directors, its controlling shareholders and its third-party service providers. As per their responses, none of the Company, nor its executive officers, directors or, its controlling shareholders nor third-party services providers have been involved in any way with the creation or distribution of promotional materials or activities.
Additionally, neither the Company’s executive officers, directors nor, to the knowledge of the Company, any controlling shareholders or any third-party service providers, has sold or purchased shares of common stock of the Company in the public market within the last 90 days.
Furthermore, the Company has not, other than disclosed in its periodic reports filed with the Securities and Exchange Commission, issued any shares or convertible instruments’ allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance.
OneLife Technologies Corp. encourages those interested in the Company to rely solely on information included in its press releases combined with its filings and disclosures made with the Securities and Exchange Commission.
“Our internal investigation regarding the recent unsanctioned promotional activities remains ongoing,” stated Robert Wagner, CEO of OneLife Technologies, Corp. “In the meantime, we remain excited and extremely committed to the execution of our business plan, and we are looking forward to providing updates to our shareholders and the investment community in the near future,” added Wagner.
ABOUT ONELIFE TECHNOLOGIES CORP.
OneLife Technologies Corp. (OTC Pink: OLMM), is a mobile medical software/data collection company with a suite of proprietary, patented, medical grade wearable tracking technologies designed to provide patients, physicians, nursing homes, and hospitals with 24/7 real-time centralized, personal, comprehensive health data. The Company files periodic reports with the Securities and Exchange Commission, which can be viewed at www.sec.gov. For more information, visit: www.onelifetc.com
Contact: Robert J. Wagner President & CEO OneLife Technologies Corporation Phone: (708) 469-7378 Email: [email protected]


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Washington Post Publisher Will Lewis Steps Down After Layoffs
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



